Top Markets
Coin of the day
Eikon Therapeutics, Inc. Common Stock Eikon Therapeutics, Inc. Common Stock

Eikon Therapeutics, Inc. Common Stock

EIKN
Classement en actions #12325
Eikon Therapeutics, Inc. is a clinical biopharmaceutical company, established... Eikon Therapeutics, Inc. is a clinical biopharmaceutical company, established in 2019 and headquartered in Millbrae, California, operating within the United States. The company is dedicated to developing groundbreaking medicines to address significant unmet medical needs. It utilizes a proprietary platform capable of precisely characterizing protein interactions inside living cells. Eikon's drug pipeline includes EIK1001, a systemically delivered TLR 7/8 dual-agonist designed to activate both innate and adaptive anti-cancer immune responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors for ovarian, breast, prostate, and pancreatic cancers. Notably, EIK1004 is brain-penetrant, offering a therapeutic approach for brain metastases and primary brain malignancies. Additionally, EIK1005 is a potent WRN helicase inhibitor and anti-tumor agent aimed at MSI-high tumors, alongside EIK1006.
Prix de l'action
$11.03
Dernière synchronisation: 2026-08-28
Capitalisation boursière
$597.15M
Changement (1 jour)
-4.25%
Changement (1 an)
-
Pays
US
Échange Eikon Therapeutics, Inc. Common Stock (EIKN)

Catégorie

Ratio P/S pour Eikon Therapeutics, Inc. Common Stock (EIKN)
Ratio P/S au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de Eikon Therapeutics, Inc. Common Stock, le ratio cours/ventes actuel (TTM) est 0. À la fin de 2026, le ratio P/S était de 0.
Historique du ratio P/S pour Eikon Therapeutics, Inc. Common Stock de 2026 à 2026
Ratio P/S à la fin de chaque année
Année Ratio P/S Changez
Pas assez de données pour les dates fournies.
Ratio P/S pour des entreprises similaires ou concurrentes
Entreprise Ratio P/S Différence de Ratio P/S Pays
10.17 -
US
10.13 -
NL
2.95 -
AU
11.28 -
US
- -
CH